Cargando…

Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review

Polycythemia vera (PV) is one of the myeloproliferative neoplasms and has higher frequency of the JAK2 V617F mutation. Hemorrhagic stroke is rare in PV, and myelofibrosis is secondary to PV. A 76-year-old Japanese man was diagnosed as PV with the JAK2 V617F mutation at the age of 63 years. He develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasui, Hidenari, Iseki, Tatou, Ueno, Yuji, Kamiyama, Daiki, Miyamoto, Nobukazu, Kijima, Chikage, Hira, Kenichiro, Komatsu, Norio, Hattori, Nobutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Single Case − General Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247523/ https://www.ncbi.nlm.nih.gov/pubmed/35949202 http://dx.doi.org/10.1159/000525171

Ejemplares similares

Association of blood eicosapentaenoic acid levels with intracerebral hemorrhage during the COVID-19 pandemic: preliminary experience from a single-center in Japan
por: Hira, Kenichiro, et al.
Publicado: (2022)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
por: Ueno, Yuji, et al.
Publicado: (2020)

Baseline platelet count may predict short-term functional outcome of cerebral infarction
por: Kanazawa, Kazo, et al.
Publicado: (2022)

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
por: Fei, Naomi, et al.
Publicado: (2017)

Characteristics of Clinical Symptoms, Cerebral Images and Stroke Etiology in Vertebro-Basilar Artery Fenestration-Related Infarction
por: Miyamoto, Nobukazu, et al.
Publicado: (2020)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Progression of primary myelofibrosis to polycythemia vera: A case report
por: Guo, Yan, et al.
Publicado: (2017)

Cluster-Like Headache Revealing Polycythemia Vera: A Case Report
por: Popescu, Cyprian
Publicado: (2020)

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
por: Song, Jinming, et al.
Publicado: (2017)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Neuropsychiatric disturbance detecting polycythemia vera myelofibrosis: a case report and literature review
por: Li, Li, et al.
Publicado: (2023)

Microbial lipopolysaccharide‐induced inflammation contributes to cognitive impairment and white matter lesion progression in diet‐induced obese mice with chronic cerebral hypoperfusion
por: Inaba, Toshiki, et al.
Publicado: (2023)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?
por: Silver, Richard T.
Publicado: (2020)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson’s Disease?
por: Iseki, Tatou, et al.
Publicado: (2023)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis
por: Lighezan, Diana L., et al.
Publicado: (2020)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Agarwal, M. B., et al.
Publicado: (2015)

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
por: Habberstad, Andreas Hanssønn, et al.
Publicado: (2018)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
por: Pimpinelli, Fulvia, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8kp076c6m61n8c4brdd6i3cr8k